A Double-blind, Placebo-controlled, Randomized Dose Ranging Trial to Determine the Safety and Efficacy of Three Dose Levels of EMA401 in Reducing 24-hour Average Pain Intensity Score in Patients With Post-herpetic Neuralgia
Phase of Trial: Phase II
Latest Information Update: 18 Jan 2019
At a glance
- Drugs Olodanrigan (Primary)
- Indications Neuropathic pain; Postherpetic neuralgia
- Focus Therapeutic Use
- Acronyms EMPHENE
- Sponsors Novartis; Novartis Pharma A.G.; Novartis Pharmaceuticals
- 27 Nov 2018 Planned End Date changed from 4 Sep 2019 to 28 Aug 2020.
- 27 Nov 2018 Planned primary completion date changed from 28 Aug 2019 to 21 Aug 2020.
- 02 Oct 2018 Planned primary completion date changed from 4 Sep 2019 to 28 Aug 2019.